COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,082 Articles (22,658 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 1126: Articles 11251-11260  | Next

REGEN-COV for the Treatment of Hospitalized Patients with Covid-19
Somersan-Karakaya, S., Mylonakis, E., Menon, V. P., Wells, J. C., Ali, S., Sivapalasingam, S., Sun, Y., Bhore, R., Mei, J., Miller, J., Cupelli, L., Hooper, A. T., Hamilton, J. D., Pan, C., Pham, V., Zhao, Y., Hosain, R., Mahmood, A., Davis, J. D., Turner, K. C., Kim, Y., Cook, A., Kowal, B., Soo, Y., DiCioccio, A. T., Geba, G. P., Stahl, N., Lipsich, L., Braunstein, N., Herman, G. A., Yancopoulos, G. D., Weinreich, D. M., the Covid-19 Phase 2/3 Hospitalized Trial Team
10.1101/2021.11.05.21265656 — Posted: 2021-11-08
Surveillance of COVID-19 in a Vaccinated Population: A Rapid Literature Review
Egunsola, O., Farkas, B., Flanagan, J., Salmon, C., Mastikhina, L., Clement, F.
10.1101/2021.11.05.21265763 — Posted: 2021-11-08
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo, M., Moya, J., Falci, D., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Parra, S., Sager, J. E., Austin, D. J., Peppercorn, A., Alexander, E., Yeh, W. W., Brinson, C., Aldinger, M., Shapiro, A. E.
10.1101/2021.11.03.21265533 — Posted: 2021-11-08
Accelerated decline of genome heterogeneity in the SARS-CoV-2 coronavirus
Oliver, J. L., Bernaola-Galvan, P., Perfectti, F., Gomez-Martin, C., Verdu, M., Moya, A.
10.1101/2021.11.06.467547 — Posted: 2021-11-08
Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen
Liu, S., Chou, C.-K., Wu, W. W., Luan, B., Wang, T. T.
10.1101/2021.11.04.467291 — Posted: 2021-11-08
Ranking the Effectiveness of Non-Pharmaceutical Interventions to Counter COVID-19 in UK Universities with Vaccinated Population
Niu, Z., Scarciotti, G.
10.1101/2021.11.07.21266028 — Posted: 2021-11-08
National and subnational short-term forecasting of COVID-19 in Germany and Poland, early 2021
Bracher, J., Wolffram, D., Deuschel, J., Goergen, K., Ketterer, J. L., Ullrich, A., Abbott, S., Barbarossa, M. V., Bertsimas, D., Bhatia, S., Bodych, M., Bosse, N. I., Burgard, J. P., Fiedler, J., Fuhrmann, J., Funk, S., Gambin, A., Gogolewski, K., Heyder, S., Hotz, T., Kheifetz, Y., Kirsten, H., Krueger, T., Krymova, E., Leithaeuser, N., Li, M. L., Meinke, J. H., Miasojedow, B., Mohring, J., Nouvellet, P., Nowosielski, J. M., Ozanski, T., Radwan, M., Rakowski, F., Scholz, M., Soni, S., Srivastava, A., Gneiting, T., Schienle, M.
10.1101/2021.11.05.21265810 — Posted: 2021-11-08
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY
Green, A. C., Curtis, H. J., Hulme, W. J., Williamson, E. J., McDonald, H. I., Bhaskaran, K., Rentsch, C. T., Schultze, A., MacKenna, B., Mahalingasivam, V., Tomlinson, L., Walker, A. J., Fisher, L., Massey, J., Andrews, C. D., Hopcroft, L. E. M., Morton, C. E., Croker, R., Morley, J., Mehrkar, A., Bacon, S. C., Evans, D., Inglesby, P., Hickman, G., Ward, T., Davy, S., Mathur, R., Tazare, J., Eggo, R. M., Wing, K., Wong, A. Y., Forbes, H., Bates, C., Cockburn, J., Parry, J., Hester, F., Harper, S., Douglas, I. J., Evans, S. J., Smeeth, L., Goldacre, B.
10.1101/2021.11.08.21265380 — Posted: 2021-11-08
Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine
Mahasirimongkol, S., Khunphon, A., Kwangsukstid, O., Sapsutthipas, S., Wichaidit, M., Rojanawiwat, A., Wichuckchinda, N., Puangtubtim, W., Sapsutthipas, S., Pimpapai, W., Soonthorncharttrawat, S., Wanitchang, A., Jongkaewwattana, A., Srisutthisamphan, K., Phainupong, D., Thawong, P., Piboonsiri, P., Sawaengdee, W., Somporn, T., Ritthitham, K., Phumiamorn, S., Pinyosukhee, N., Wichajarn, R., Dhepaksorn, P., Iamsiritahworn, S., Phumiamorn, S.
10.1101/2021.11.05.21264700 — Posted: 2021-11-08
A need of COVID19 vaccination for children aged <12 years: Comparative evidence from the clinical characteristics in patients during a recent Delta surge (B.1.617.2)
Li, H., Lin, H., Chen, X., Li, H., Li, H., Lin, S., Huang, L., Chen, G., Zheng, G., Wang, S., Hu, X., Huang, H., Tu, H., Li, X., Ji, Y., Zhong, W., Li, Q., Fang, J., Lin, Q., Yu, R., Xie, B.
10.1101/2021.11.05.21265712 — Posted: 2021-11-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).